Dx & Vx Co., Ltd.
Financials
Valuation Metrics
Dx & Vx Co., Ltd.'s Market Cap is ₩2510B. At end of 2025 it was ₩3091B. Ranked #712 of 2,436 in KR market (top 29%), #303 of 1,649 on KOSDAQ (top 18%), #80 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 34%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 251.00B KRW | KR#712/2,436 Sec#80/234 |
| Revenue | 28.48B KRW | KR#2,049/2,436 Sec#145/234 |
| Net Income | -28.63B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 115.39B KRW | KR#1,643/2,436 Sec#134/234 |
| Net Assets | 90.79B KRW | KR#1,462/2,436 Sec#120/234 |
| Employees | 121 | KR#1,487/2,436 Sec#118/234 |
| Value | ||
| P/B | 2.76x | KR#2,083/2,436 Sec#163/234 |
| P/S | 8.81x | KR#2,254/2,436 Sec#158/234 |
| FCF Yield | -7.91% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -31.53% | KR#2,178/2,436 Sec#175/234 |
| ROA | -24.81% | KR#2,258/2,436 Sec#185/234 |
| Op. Margin | -80.35% | KR#2,292/2,436 Sec#170/234 |
| Revenue Growth | -11.60% | KR#1,919/2,436 Sec#177/234 |
| Financial Health | ||
| Debt Ratio | 127.10% | KR#798/2,436 Sec#94/234 |
| Total Debt | 16.68B KRW | KR#1,427/2,436 Sec#120/234 |
| FCF | -19.85B KRW | KR#1,898/2,436 Sec#179/234 |
| Cash | 62.23B KRW | KR#650/2,436 Sec#32/234 |
| Current Ratio | 5.08x | KR#287/2,436 Sec#54/234 |
| Performance | ||
| 1Y Return | 2.82% | KR#653/2,436 Sec#47/234 |
| 1M Return | 6.47% | KR#399/2,436 Sec#29/234 |
| From 52W High | -52.43% | KR#1,317/2,436 Sec#110/234 |
| 1Y MDD | -61.19% | KR#1,481/2,436 Sec#117/234 |
| Trading | ||
| Volume | 80,225 shares | KR#1,064/2,436 Sec#102/234 |
| Foreign Own. | 5.07% | KR#795/2,436 Sec#76/234 |
| Per Share | ||
| EPS | -456 KRW | KR—/2,436 Sec—/234 |
| BPS | 904 KRW | KR#2,305/2,436 Sec#209/234 |
Company Info
DXVX, established in 2001, is a bio-healthcare specialized company that listed on KOSDAQ in 2015. It has expanded its business through the acquisition of Korea Biopharm in 2022, and the establishment of a Chinese subsidiary and acquisition of Evixgen in 2023. The medical diagnostics division focuses on NGS and DNA chip-based genomic diagnostics, along with the development and manufacturing of PCR molecular diagnostic and rapid immune diagnostic kits. The new drug development division aims to reduce financial risk by developing diverse pipelines and implementing stage-by-stage license transfers. DXVX is headquartered in Geumcheon-gu, Seoul.